Advancing Excellence in Peptide Research
3rd Party Tested in the USA
$103.95
ACE-031 was developed as a myostatin inhibitor to enhance muscle growth and treat muscle-wasting diseases. While early research showed promise, development was halted due to safety concerns. Because ACE-031 is not approved for clinical use and lacks long-term safety data, extreme caution is advised regarding any products claiming to contain it.
Out of stock
ACE-031 is a synthetic peptide and modified form of a myostatin-blocking protein. It was developed by Acceleron Pharma with the goal of inhibiting myostatin, a naturally occurring protein that limits muscle growth. By blocking myostatin, ACE-031 was designed to promote muscle hypertrophy and improve muscle mass, making it a potential therapy for conditions such as muscular dystrophy, sarcopenia, and other muscle-wasting disorders.
Research on ACE-031 began in the late 2000s, with early clinical trials evaluating its safety, tolerability, and effectiveness in humans. Although results showed potential for increasing muscle mass, development of ACE-031 was halted after Phase 2 clinical trials due to safety concerns and adverse effects, preventing it from reaching approval or commercial use.
The potential benefits of ACE-031 include:
Increased Muscle Mass
ACE-031 is designed to inhibit myostatin, which can significantly promote muscle growth and increase lean muscle mass.
Improved Muscle Function
In individuals with muscle-wasting conditions, ACE-031 may improve muscle performance, strength, and physical capability.
Potential Treatment for Muscle-Wasting Diseases
ACE-031 showed early promise in research targeting muscular dystrophy and other disorders that result in severe muscle loss.
Enhanced Recovery
By supporting muscle growth and strength, ACE-031 may potentially improve recovery speed following injuries or surgeries.
ACE-031 is not approved by the FDA or other regulatory agencies for human use. Its development was discontinued, and its long-term safety and efficacy remain unproven.
Clinical trials identified potential adverse effects, which contributed to the termination of its development. The long-term risks—especially regarding chronic myostatin inhibition—are not well understood.
Individuals seeking muscle growth or recovery support should consult a healthcare professional for safe, evidence-based alternatives. Because ACE-031 is unregulated and discontinued, its use poses significant risks.
Reviews
There are no reviews yet.